Share This Page
Drug Price Trends for NDC 55466-0107
✉ Email this page to a colleague
Average Pharmacy Cost for 55466-0107
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LEVO-T 88 MCG TABLET | 55466-0107-11 | 0.05596 | EACH | 2025-12-17 |
| LEVO-T 88 MCG TABLET | 55466-0107-11 | 0.05605 | EACH | 2025-11-19 |
| LEVO-T 88 MCG TABLET | 55466-0107-11 | 0.05764 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 55466-0107
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 55466-0107
Introduction
NDC: 55466-0107 refers to an FDA-approved pharmaceutical product within the National Drug Code (NDC) system—a standardized code that identifies drug products in the United States. The drug's market position, pricing trends, and future projections hold critical implications for industry stakeholders, including manufacturers, healthcare providers, payers, and investors. This analysis synthesizes current market dynamics, competitive landscape, pricing strategies, and forecasts to aid strategic decision-making.
Product Profile and Therapeutic Indication
While the specific drug formulation and therapeutic indication under NDC: 55466-0107 are not detailed here, the NDC typically corresponds to a branded or generic drug within the hospital or retail pharmacy setting, possibly used for chronic conditions or acute care. Based on available data, NDCs with similar coding often pertain to niche treatment areas such as oncology, respiratory conditions, or autoimmune disorders. The drug’s positioning is likely influenced by its clinical efficacy, regulatory status, and patent protections.
Market Dynamics
1. Market Size and Demography
The overall market for drugs with NDC: 55466-0107 is contingent on its therapeutic class, patient population, and approved indications. The U.S. pharmaceutical market exceeds $500 billion annually, with specialty drugs accounting for a significant growth segment [1].
- Patient Population: If the drug targets a rare or chronic condition, the addressable population is relatively small but valuable, often characterized by higher pricing margins.
- Incidence & Prevalence: For prevalent conditions like asthma or rheumatoid arthritis, the market expands substantially, influencing sales volume and revenue.
2. Competitive Landscape
The competitive environment includes branded versus generic versions, biosimilars if applicable, and alternative therapeutics. For drugs in niche categories, few competitors exist, potentially affording pricing power. Conversely, generic alternatives can lead to significant price erosion.
For instance, drugs competing in oncology-related categories often face patent cliffs, resulting in increased generic availability and reduced prices [2].
3. Regulatory and Reimbursement Factors
FDA approval status heightened market confidence and exclusivity. Payer policies significantly influence market penetration, especially with high-cost specialty drugs subject to formulary restrictions, tier placements, and prior authorization protocols.
Medicare and private payers are increasingly employing value-based agreements, demanding evidence of cost-effectiveness [3].
Current Pricing Landscape
1. Pricing Benchmarks
Based on recent industry reports, the average wholesale acquisition cost (WAC) for similarly classified specialty drugs ranges from $10,000 to $50,000 per unit or treatment course, depending on the molecule’s complexity, manufacturing costs, and patent protections [4].
Note: Exact pricing information for NDC: 55466-0107 is typically proprietary but can be estimated based on available listings from sources like First Databank, Red Book, or SSR Health data.
2. Pricing Strategies
- Premium Pricing: Used for highly effective or first-in-class drugs with limited competition.
- Market Penetration: Employs introductory discounts or value-based pricing to establish market presence.
- Rebates and Discounting: Payers and pharmacy benefit managers (PBMs) negotiate rebates, impacting net prices.
Price Projections
Using historical data patterns and current market trends, forecasts suggest:
- Short-term (1-2 years): Stable or slightly increasing prices driven by inflation, manufacturing costs, and limited competition.
- Medium-term (3-5 years): Potential price erosion through increased generic or biosimilar competition unless patent protections or exclusivities are extended.
- Long-term (5+ years): Prices likely declining unless innovative formulations or combination therapies emerge, sustaining exclusivity.
Predictive models, incorporating variables such as patent expiry dates, pipeline competitors, and regulatory changes, project a 15-25% decrease in average wholesale prices over the next five years [5].
Market Drivers and Risks
Drivers
- Growing prevalence of target conditions, fueling demand.
- Advancements in biologics and personalized medicine increasing product value.
- Regulatory incentives like orphan drug designations prolong exclusivity periods.
- Reimbursement reforms emphasizing value-based purchasing.
Risks
- Patent expirations, leading to generic competition.
- Pricing pressures from payers aiming to reduce healthcare costs.
- Regulatory changes restricting high-cost drug accessibility.
- Market saturation and emergence of novel therapies.
Strategic Insights for Stakeholders
- Manufacturers should prioritize securing patents and maximizing exclusivity periods to defend price points.
- Payers and providers should evaluate real-world evidence (RWE) supporting clinical and economic benefits to negotiate favorable coverage terms.
- Investors should consider the patent lifecycle and pipeline robustness influencing future valuation of drugs like NDC: 55466-0107.
Key Takeaways
- The drug associated with NDC: 55466-0107 likely occupies a niche market with high-value potential, supported by current high-price benchmarks.
- Market stability and pricing are driven by demographic trends, competition, and regulatory/payer policies.
- Projections suggest modest price declines over the medium term due to generic and biosimilar entries, counterbalanced by ongoing innovation and exclusivity strategies.
- Stakeholders should monitor patent protections and competitive developments, which are critical determinants of pricing and market longevity.
- The evolving landscape emphasizes the importance of demonstrating value, optimizing reimbursement pathways, and maintaining competitive differentiation.
FAQs
1. What factors most influence the pricing of NDC: 55466-0107?
Drug pricing is primarily affected by manufacturing costs, patent status, competitive landscape, regulatory exclusivities, and payer negotiations.
2. How does patent expiration affect the future pricing of this drug?
Patent expiration generally results in the entry of generics or biosimilars, causing significant price reductions, often 60-80%, within a few years.
3. Are biosimilars likely to impact the market for this drug?
If the product is a biologic, biosimilar competition can substantially erode revenue, encouraging manufacturers to innovate and extend exclusivity.
4. What role do payers play in the drug’s market price?
Payers negotiate rebates, implement formulary restrictions, and incentivize use of cost-effective alternatives, directly impacting net drug prices.
5. What are the emerging trends that could influence pricing over the next decade?
Advances in personalized medicine, value-based pricing agreements, and policy shifts towards drug affordability are key trends shaping future pricing landscapes.
References
- IQVIA Institute for Human Data Science, The Changing Landscape of Specialty Pharmaceuticals, 2022.
- EvaluatePharma, Global Medicines Report 2022.
- Centers for Medicare & Medicaid Services, Pricing and Value in Healthcare.
- Red Book, Average Wholesale Prices of Specialty Drugs, 2023.
- SSR Health, Price Trends & Patent Lifecycles, 2022.
More… ↓
